<DOC>
	<DOCNO>NCT02286635</DOCNO>
	<brief_summary>The primary objective study determine potential effect multiple dos rifampin clarithromycin single dose pharmacokinetics ( PK ) deflazacort active metabolite ( 21 desacetyl-DFZ ) healthy adult subject .</brief_summary>
	<brief_title>Evaluate Effects Multiple Doses Rifampin Clarithromycin Single Dose Pharmacokinetics Deflazacort</brief_title>
	<detailed_description>This open label , parallel 2-arm , 2-period , fixed-sequence study 58 healthy adult non-tobacco use male female subject divide 2 cohort , 29 subject arm study ( Cohorts A B ) . Cohort A : On Day 1 Period 1 single oral dose deflazacort ( Treatment A ) administer follow PK sample 24 hour 21 desacetyl DFZ , data permit , deflazacort . In Period 2 , multiple oral dos rifampin administer daily ( QD ) 10 consecutive day single oral dose deflazacort coadministered Day 10 ( Treatment B ) . Pharmacokinetic sample 21-desacetyl-DFZ , data permit , deflazacort take 24 hour follow deflazacort dose Day 10 . Morning urine collection use measure 6β-hydroxycortisol free cortisol concentration Days 1 , 4 , 8 , 10 evaluate level cytochrome P450 ( CYP ) enzyme induction . Cohort B : On Day 1 Period 1 single oral dose deflazacort ( Treatment C ) administer follow PK sample 24 hour 21-desacetyl-DFZ , data permit , deflazacort . In Period 2 , multiple oral dos clarithromycin administer twice daily ( BID ) 4 consecutive day single oral dose deflazacort coadministered morning Day 4 ( Treatment D ) . Pharmacokinetic sample 21 desacetyl-DFZ , data permit , deflazacort take 24 hour follow deflazacort dose Day 4 . Both Cohorts A B : There least 24 hour dose Period 1 first dose Period 2 . Safety monitor throughout study repeat clinical laboratory evaluation . The clinic attempt contact subject use standard procedure approximately 14 day last study drug administration determine adverse event ( AEs ) occur since last dose study drug . Subjects terminate study early contact Principal Investigator ( PI ) deem necessary . Cohort A : Treatments A B described follow : Treatment A ( Period 1 ) : 18 mg deflazacort ( 3 x 6 mg tablet ) Hour 0 Day 1 , follow overnight fast . Treatment B ( Period 2 ) : 600 mg rifampin ( 2 x 300 mg capsule ) administer Hour 0 overnight fast every 24 hour 10 day ( within ± 1 hour dosing time Day 1 ) , 18 mg deflazacort ( 3 x 6 mg tablet ) coadministered Day 10 . Cohort B : Treatments C D describe follow : Treatment C ( Period 1 ) : 18 mg deflazacort ( 3 x 6 mg tablet ) Hour 0 Day 1 , follow overnight fast . Treatment D ( Period 2 ) : 500 mg clarithromycin ( 1 x 500 mg tablet ) administer Hour 0 Hour 12 , fast condition , approximately every 12 hour , 4 day ( within ± 1 hour dose time Day 1 ) , 18 mg deflazacort ( 3 x 6 mg tablet ) coadministered Hour 0 morning Day 4 . The final dose clarithromycin give Hour 12 even Day 4 . All study drug cohort administer orally approximately 240 mL water .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<criteria>Healthy , adult , male female , 18 55 year age Continuous non smoker use nicotine containing product least 3 month Body mass index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 For female non childbearing potential : must undergo sterilization procedure postmenopausal amenorrhea least 1 year prior first dose study drug FSH serum level consistent postmenopausal status A non vasectomize , male subject must agree use condom spermicide abstain sexual intercourse study 90 day If male , must agree donate sperm first dose study drug 90 day Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study History presence alcoholism drug abuse within past 2 year History presence hypersensitivity idiosyncratic reaction study drug relate compound ( e.g. , steroid formulation include lactose ) History presence : 1 . Symptomatic cardiomyopathy screen 2 . Immunosuppression contraindication corticosteroid treatment 3 . History chronic systemic fungal viral infection 4 . Galactose intolerance , Lapp lactose deficiency , glucosegalactose malabsorption 5 . Diabetes mellitus 6 . Osteoporosis 7 . Myasthenia gravis 8 . Epilepsy 9 . Idiopathic hypocalcuria 10 . Hypothyroidism ( TSH clinically significant ) 11 . Gastrointestinal issue ulcer 12 . Previous corticoidsinduced myopathy 13 . Ocular herpes simplex Female subject childbearing potential Female subject pregnant lactate Positive urine drug alcohol result Positive urine cotinine Positive result HIV , HBsAg HCV Seated blood pressure le 90/40 mmHg great 140/90 mmHg Seated heart rate lower 40 bpm high 99 bpm QTc interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) Has receive live liveattenuated vaccine within 30 day Has receive immunosuppressive agent , coal tar , and/or radiation therapy within 30 day Has receive injectable corticoid 12 week dose study drug oral form corticoid 30 day Estimated creatinine clearance &lt; 80 ml/min Unable refrain anticipates use Any drug , include prescription non prescription medication , well herbal remedy know significant inhibitor CYP 3A4 enzyme and/or P gp 14 day Any drug know significant inducer CYP 3A4 enzyme and/or P gp , include St. John 's Wort , 28 day Have diet incompatible study diet within 28 day Donation blood significant blood loss within 56 day Plasma donation within 7 day Participation another clinical trial within 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>